The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Effects of ipsapirone and cannabidiol on human experimental anxiety
Abstract
The effects of ipsapirone and cannabidiol (CBD) on healthy volunteers submitted to a simulated public speaking (SPS) test were compared with those of the anxiolytic benzodiazepine diazepam and placebo. Four independent groups of 10 subjects received, under a double-blind design, placebo or one of the following drugs: CBD (300 mg), diazepam (10 mg) or ipsapirone (5 mg). Subjective anxiety was evaluated through the Visual Analogue Mood Scale (VAMS) and the State-trait Anxiety Inventory (STAI). The VAMS anxiety factor showed that ipsapirone attenuated SPS-induced anxiety while CBD decreased anxiety after the SPS test. Diazepam, on the other hand, was anxiolytic before and after the SPS test, but had no effect on the increase in anxiety induced by the speech test. Only ipsapirone attenuated the increase in systolic blood pressure induced by the test. Significant sedative effects were only observed with diazepam. The results suggest that ipsapirone and CBD have anxiolytic properties in human volunteers submitted to a stressful situation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In human studies, the anxiolytic effects of CBD have been elicited in subjects submitted to the Simulation Public Speaking Test (SPST) (Zuardi et al, 1993).”
From Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients (2011) · cites this paper as Zuardi et al, 1993
In the citing paper
“acute anxiolytic effects of CBD have been observed in healthy controls with doses ranging from 300 (Zuardi et al, 1993) to 600 mg (Fusar-Poli et al, 2009a, 2009b).”
From Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients (2011) · cites this paper as Zuardi et al, 1993
In the citing paper
“A factorial analysis performed with the Portuguese version of the VAMS also yielded four factors with similar item composition (Zuardi et al, 1993).”
From Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients (2011) · cites this paper as Zuardi et al, 1993
In the citing paper
“and glossophobia (fear of public speaking) (Bergamaschi et al., 2011; Crippa et al., 2004; Zuardi et al., 1993)”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Zuardi et al., 1993
Citations
Cites
(1970) · Cited by 24,983
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Manual for the Wechsler Adult Intelligence Scale.
Wechsler, D. (1955) · Psychological Corp. eBooks · Cited by 4,941
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
The use of analogue scales in rating subjective feelings
BOND, A., & LADER, M. (1974) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1974.tb02285.x · Cited by 1,972
The development of a scale to measure fear
Geer, J. H. (1965) · Behaviour Research and Therapy · doi:10.1016/0005-7967(65)90040-9 · Cited by 777
Action of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjects
Zuardi, A. W., Shirakawa, I., Finkelfarb, E., & Karniol, I. G. (1982) · Psychopharmacology · doi:10.1007/bf00432554 · Cited by 608
Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients
Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R. J., Sanvito, W. L., Lander, N., & Mechoulam, R. (2008) · Pharmacology · doi:10.1159/000137430 · Cited by 570
Pertwee, R. G. (1977) · Neuroscience · doi:10.1016/0306-4522(77)90080-x · Cited by 384
The action of sedatives on brain stem oculomotor systems in man
Norris, H. (1971) · Neuropharmacology · doi:10.1016/0028-3908(71)90039-6 · Cited by 384
Antianxiety effect of cannabidiol in the elevated plus-maze
Guimarães, F. S., Chiaretti, T. M., Graeff, F. G., & Zuardi, A. W. (1990) · Psychopharmacology · doi:10.1007/bf02244012 · Cited by 379
Goa, K. L., & Ward, A. (1986) · Drugs · doi:10.2165/00003495-198632020-00002 · Cited by 333
Controlled clinical trial of cannabidiol in Huntington's disease
Consroe, P. F., Laguna, J., Allender, J. R., Snider, S. R., Stern, L. Z., Sandyk, R., Kennedy, K., & Schram, K. H. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90386-g · Cited by 324
Pharmacological characterization of cannabinoids in the elevated plus maze.
Onaivi, E. S., Green, M. R., & Martin, B. R. (1990) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13195-9 · Cited by 312
Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man
Karniol, I. G., Shirakawa, I., Kasinski, N., Pfeferman, A., & Carlini, E. A. (1974) · European Journal of Pharmacology · doi:10.1016/0014-2999(74)90129-0 · Cited by 303
Pharmacological interaction between cannabidiol and ?9-tetrahydrocannabinol
Karniol, I. G., & Carlini, E. A. (1973) · Psychopharmacology · doi:10.1007/bf00428793 · Cited by 182
Tyrer, P. J. (1988) · Oxford University Press eBooks · Cited by 166
Simulated public speaking as a model of clinical anxiety
McNair, D. M., Frankenthaler, L. M., Czerlinsky, T., White, T. W., Sasson, S., & Fisher, S. (1982) · Psychopharmacology · doi:10.1007/bf00436092 · Cited by 140
Agurell, S., Carlsson, S., Lindgren, J. E., Ohlsson, A., Gillespie, H., & Hollister, L. (1981) · Experientia · doi:10.1007/bf02085029 · Cited by 129
Intra-hippocampal buspirone in animal models of anxiety
Kostowski, W., Płaźnik, A., & Stefański, R. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90803-0 · Cited by 123
Influence of cannabidiol on delta‐9‐tetrahydrocannabinol effects
Dalton, W. S., Martz, R. C., Lemberger, L., Rodda, B. E., & Forney, R. B. (1976) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1976193300 · Cited by 123
Effect of chlorimipramine and maprotiline on experimental anxiety in humans
Guimarães, F. S., Zuardi, A. W., & Graeff, F. G. (1987) · Journal of Psychopharmacology · doi:10.1177/026988118700100305 · Cited by 110
Pharmacological interaction between cannabinol and ?9-tetrahydrocannabinol
Takahashi, R. N., & Karniol, I. G. (1975) · Psychopharmacology · doi:10.1007/bf00428937 · Cited by 97
Central Serotonin Receptors and Psychotropic Drugs
Tricklebank, M. D. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90126-7 · Cited by 88
Effect of metergoline on human anxiety
Graeff, F. G., Zuardi, A. W., Giglio, J. S., Filho, E. C. L., & Karniol, I. G. (1985) · Psychopharmacology · doi:10.1007/bf00432224 · Cited by 85
Vry, J. D., Gläser, T., Schuurman, T., Schreiber, R., & Traber, J. (1991) · doi:10.1007/978-1-349-11847-2_7 · Cited by 82
Carlini, E. A., Santos, M., Claussen, U., Bieniek, D., & KORTE, F. (1970) · Psychopharmacology · doi:10.1007/bf00402387 · Cited by 81
Gepirone in anxiety: a pilot study.
Csanalosi, I., Schweizer, E. E., CASE, W. G., & Rickels, K. (1987) · PubMed · Cited by 72
Intravenous Δ9-Tetrahydrocannabinol
Malit, L. A., Johnstone, R. E., Bourke, D. L., Kulp, R. A., Klein, V., & Smith, T. C. (1975) · Anesthesiology · doi:10.1097/00000542-197506000-00008 · Cited by 58
Teicher, M. H. (1988) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30745-3 · Cited by 56
Reduction in cortical 5HT2 receptor sensitivity after continuous gepirone treatment
Eison, A. S., & Yocca, F. D. (1985) · European Journal of Pharmacology · doi:10.1016/0014-2999(85)90648-x · Cited by 56
Nye, J. S., Seltzman, H. H., Pitt, C. G., & Snyder, S. H. (1985) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23705-3 · Cited by 54
Csanalosi, I., Schweizer, E. E., Rickels, K., & Case, G. W. (1987) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198702000-00006 · Cited by 50
Early postnatal treatment with propranolol affects development of brain amines and behavior
Hilakivi, L. A., Taira, T., Hilakivi, I. T., MacDonald, E., Tuomisto, L. M., & Hellevuo, K. (1988) · Psychopharmacology · doi:10.1007/bf00216061 · Cited by 39
Brain 5-HT1A receptor agonism: a novel mechanism for antihypertensive action
Saxena, P. R., & Villalón, C. M. (1990) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(90)90187-d · Cited by 31
Lovick, T. A. (1990) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/bf00370249 · Cited by 30
A simple simulated public speaking test for evaluating anxiolytic drugs.
Fs, G., Cl, K., Gus, G., Hs, F., Mc, D.-V., Cl, D.-P., Ribeiro, A. M., Cc, T., & Wannmacher, L. (1989) · PubMed · Cited by 27
5 ht receptor subtypes and the modulation of aversion
Deakin, J. F. W., Graeff, F. G., & Guimarães, F. S. (1992) · Cited by 24
5-HT Receptor Mechanisms in Human Anxiety
Deakin, J. F. W., Guimarães, F. S., Wang, M., Hellewell, J. S. E., & Hensman, R. (1991) · doi:10.1007/978-1-349-11847-2_6 · Cited by 13
Research works printed but not linked: 10
- Biaggio A M B, 1976, Cross-cultural research on anxiety., 29
- Critchley M A E, 1987, Br J Pharmacol, 92, 660
- Geer J H, 1965, Behav Res Ther, 193, 785
- Gregg J M, 1976, J Oral Surg, 34, 301
- Guimarães F S, 1989, Brazilian J Med Biol Res, 22, 1083
- Higgins G A, 1987, Br J Pharmacol, 92, 658P
- Kuemmel B, 1988, Psychopharmacology, 96, 353, 10.1007/BF00216061 · DOI
- Norusis M J, 1988, SPSS/PC + advanced stataistics V. 2.0
- Zuardi A W, 1981, J Brasileiro Psiquiatr, 131, 403
- Zuardi A W, 1983, Ar Biol Technol, 26, 391
Cited by
Sorted by citations
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771
Cannabidiol as a Potential Treatment for Anxiety Disorders
Blessing, E., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0387-1 · Cited by 752
Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O' Carroll, C. M., Seal, M., Allen, P., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.184 · Cited by 680
Safety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558
Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379283 · Cited by 535
Metadata
- Authors
- Zuardi, A. W., Cosme, R. A., Graeff, F. G., & Guimarães, F. S.
- Affiliations
- Universidade de São Paulo (BR)
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 1993-01
- Volume
- 7
- Issue
- 1_suppl
- Pages
- 82-88
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W1696206979
- Cited by
- 364
- References
- 39
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 33 · 2023: 28 · 2022: 37 · 2021: 28 · 2020: 43 · 2019: 25 · 2018: 11 · 2017: 21 · 2016: 12 · 2015: 12 · 2014: 9 · 2013: 10 · 2012: 17
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- ipsapirone, cannabidiol, diazepam, anxiety, anxiolytic effects, stress response, blood pressure, sedation, healthy volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
